Skip to main content
main-content

COVID-19 and rheumatic disease

Latest news, guidance, and expert opinion for rheumatology professionals
Spotlight on: COVID-19 in rheumatic disease patients

Telemedicine in rheumatology: COVID-19 and beyond

Telemedicine

We talk to the experts about the increasing use of telemedicine in rheumatology during the COVID-19 pandemic, exploring what needs to be considered for different rheumatic diseases and whether telerheumatology is here to stay.

Trial suggests no benefit of tocilizumab for COVID-19

John Stone

John Stone talks about the BACC Bay Tocilizumab Trial, which demonstrated similar outcomes among hospitalized COVID-19 patients treated with the IL-6 inhibitor versus placebo in addition to standard care (6:47).

Spotlight on: Repurposing rheumatology drugs for COVID-19

Early RCT evidence suggests tocilizumab may not be beneficial for COVID-19

Covid emergency treatment in hospital

Findings from three randomized controlled trials suggest that treatment with the IL-6 inhibitor tocilizumab has little benefit for hospitalized patients with COVID-19.


Guidance for rheumatologists

Guidance and expert opinion on rheumatology practice during the COVID-19 pandemic


COVID-19 in rheumatic disease patients

The latest research, announcements, and expert interviews on COVID-19 in patients with rheumatic diseases


Repurposing rheumatology drugs for COVID-19

The latest research and announcements on repurposing rheumatology drugs for the treatment of COVID-19

Keep up with podcasts on this topic, available on

Image Credits